Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
ALLKAllakos(ALLK) Newsfilter·2024-02-26 20:02

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical- stage biotechnology company developing therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferat ...